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OBJECTIVES We attempted to make a comprehensive assessment of the risk of stent failure (death,
myocardial infarction or angiographically documented occlusion), differentiating early (first
and second weeks) and late (third and fourth weeks) events.
BACKGROUND The risk of stent failure decreases rapidly within the first week. It has been suggested that the
risk rate for late events is close to 0% and that the thienopyridine regimen (ticlopidine or
clopidogrel) could be safely reduced from four to two weeks, minimizing the risk of
hematological complications.
METHODS We analyzed 5,678 patients with successful coronary stent placement and a four-week
ticlopidine regimen.
RESULTS The rate of stent failure was 2.5% at four weeks, with 112 early (2.0%) and 30 late events
(0.5%). Multivariate analysis identified different risk factors for early versus late events. While
variables on stenosis severity and procedural results that can be influenced by the operator
were identified as independent risk factors for early events (percent stenosis before and after
the procedure, residual dissection, length of stented segment), more clinical variables were
associated with late events (age, reduced left ventricular function, systemic hypertension as a
protective factor). The late-event rate was ,0.1% in the absence of these factors, but it was
2.5% with all three risk factors present.
CONCLUSIONS The risk of late stent failure is low with a four-week ticlopidine regimen. However, high-risk
subgroups have a risk of 2.5%. As this rate is presumably higher if thienopyridines are
discontinued after two weeks, these data suggest that a risk stratification to a two- or
four-week regimen is preferable to a general reduction. (J Am Coll Cardiol 2001;37:
2066–73) © 2001 by the American College of Cardiology
The frequency of thrombotic stent occlusion and associated
major adverse cardiac events has been dramatically reduced
by the introduction of a combined antiplatelet regimen with
aspirin and ticlopidine (1–4). In the four pivotal random-
ized trials proving efficacy, ticlopidine was given for at least
four weeks, in parallel with the previous standard anti-
thrombotic regimen of anticoagulation with aspirin plus
warfarin. In general, the risk of stent occlusion is particularly
high during the first four days (5), with a substantial
decrease afterwards. In view of this decreasing risk, the
necessary length of therapy has been disputed, and a
two-week regimen has been suggested (6,7). The predom-
inant concern is the frequent side effects of ticlopidine.
Diarrhea, nausea, vomiting and skin rashes are fairly fre-
quent. The most serious side effects, however, are neutro-
penia, which probably occurs in approximately 1% of pa-
tients who have had a four-week therapy (1,3,8–10) and,
less frequently, thrombocytopenia and thrombotic throm-
bocytopenic purpura (11). Recently, ticlopidine has widely
been replaced by clopidogrel, a newer thienopyridine deriv-
ative, after several studies have revealed a more favorable
safety profile than ticlopidine (10,12–14). Then again,
serious safety issues about clopidogrel therapy have been
raised recently (15,16), although the risk appears to be much
lower than it is with ticlopidine. The interest in limiting the
length of thieniopyridine therapy in general was further
promoted by the results of several nonrandomized trials.
These indicated that the discontinuation of either ticlopi-
dine (6,7) or clopidogrel (17) after only two weeks of
therapy was associated with a very low frequency of stent
thrombosis and associated adverse cardiac events.
However, several issues arise with all these modifications,
initially pursued to lower the approximately 1% rate of
severe hematologic side effects with a four-week ticlopidine
regimen. The requirement for thienopyridine therapy dur-
ing the first two weeks appears to be undisputed, by contrast
with the second two weeks of therapy. During this period,
the risk of stent occlusion appears to be low, perhaps close
to zero. However, the precise incidence of late stent failure
has not been determined in a large population receiving
thienopyridine therapy, and a comprehensive analysis of risk
factors for late events is lacking. Such data might allow
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differentiation between groups of patients with higher or
lower risks, leading to a differential approach and stratifi-
cation. Furthermore, the risk-benefit calculation for a four-
week versus a two-week regimen might lead to different
results for clopidogrel, considering its more favorable side-
effect profile and its presumably comparable cardiac efficacy.
We performed this retrospective study to determine the
risk of stent failure with a focus on late events during the
second two weeks and the identification of independent risk
factors for late stent failure. In this analysis, we included all
patients who were treated at our institutions and received a
four-week ticlopidine regimen.
METHODS
Patient population. This study analyzed 5,678 successful
stent-placement procedures having post-procedural com-
bined antiplatelet regimens of aspirin and ticlopidine for
four weeks’ duration. This analysis comprised all procedures
performed at our institutions from the beginning of 1994 to
the end of 1999, excluding only patients with coumadin
treatment and patients in cardiogenic shock before the
procedure. These were excluded from the analysis because
their clinical course is multifactorial. Procedural success
was defined by a residual stenosis ,30% and distal Throm-
bolysis in Myocardial Infarction (TIMI) grade flow $2. A
residual dissection did not constitute failure if flow re-
mained stable at TIMI grade 3. Procedures with final TIMI
flow grade 2 were judged to be successful only if there was
no visible residual dissection and pre-procedural flow had
been TIMI grade 0 to 1.
Stent placement and post-procedural management. No
additional alternative technique was used before (i.e., rota-
blator, laser or other debulking devices) or after stenting
(i.e., intracoronary radiation therapy). During the interven-
tion, patients received heparin (12,000 to 15,000 IE intra-
arterially) and aspirin (500 mg intravenously). Stent implan-
tation of either a slotted-tube or multicellular type was
performed either as loose stents firmly hand-crimped onto
conventional angioplasty balloon catheters (n 5 4,080) or
pre-mounted on their commercially available delivery sys-
tems (n 5 1,598). Various stent types were used: Multi-
Link stent (n 5 1,428; ACS-Guidant, Temecula, Califor-
nia), Inflow stent (n 5 1,334; Inflow Dynamics, Munich,
Germany), Palmaz-Schatz stent (n 5 1,051; Johnson &
Johnson Interventional Systems, Warren, New Jersey), Jos-
tent (n 5 735; JOMED, Rangendingen, Germany), Pura-A
(n 5 451; Devon Medical, Hamburg, Germany), NIR stent
(n 5 308; Scimed-Boston Scientific, Maple Grove, Min-
nesota) and several other types in ,60 procedures (total n 5
371). Procedural results were assessed by angiography only;
no intravascular ultrasound studies were utilized. All pa-
tients were given ticlopidine (250 mg twice a day, Tiklyd,
Sanofi-Winthrop, Munich, Germany) for four weeks in
addition to aspirin (100 mg twice a day, indefinitely). Most
patients received a loading regimen for ticlopidine with
three doses of 500 mg, started as early as possible before or
immediately after the intervention (,30 min after the
procedure). The study period comprises the introduction of
glycoprotein IIb/IIIa inhibitors. Overall, abciximab was
administered in 1,943 procedures (34.2%); it increased from
7.4% in the first year to 64.8% in the last year to become
routine for patients with acute coronary syndromes, with
visible intracoronary thrombi, or with flow-limiting dissec-
tions or occlusion during the procedure.
A complete 30-day follow-up is available for all proce-
dures; all patients were seen as outpatients one month after
discharge or contacted by telephone.
Definitions. “Stent failure” was defined as either death,
myocardial infarction (MI) (episode of typical chest pain,
new pathological Q waves or creatine kinase rise .3 times
the upper limit of normal [.240 U/l] with concomitant
increase of the MB isoenzyme) or angiographically docu-
mented stent vessel occlusion. These events were differen-
tiated as “early” if they occurred within the first 14 days and
“late” for events during days 15 to 30. A “reduced left
ventricle (LV) function” was defined as an ejection fraction
,50%. The “length of stented segment” was the sum of the
length of all stents implanted in the coronary segment. A
“residual dissection” was noted by the operator at the end of
the procedure in the presence of a dissection .5 mm in the
stented or adjacent segment. In this setting, the procedure
was considered successful only if flow was TIMI grade 3.
Data analysis and statistics. Quantitative angiographic
analysis was performed off-line on a commercially available
system with edge detection algorithms (CMS, Medis Med-
ical Imaging Systems, Nuenen, The Netherlands) by trained
technicians not involved in the procedures. Data were
continuously assessed and entered into a relational database.
Clinical data were recorded to define procedures; angio-
graphic data were assessed for individual lesions treated
during a procedure.
Analyses were performed with S-Plus software (Math-
Soft, Seattle, Washington), expanded by a function library
by Harrell (18). Statistical significance was assumed at p
,0.05. The risk of stent failure was analyzed per logistic
regression analysis; all factors with p value ,0.10 by
univariate comparison were entered into this analysis. Rel-
Abbreviations and Acronyms
ATLAST 5 Antiplatelet Therapy versus
Antiplatelet Therapy Alone in
Patients at Increased Risk of Stent
Thrombosis trial
CART 5 classification and regression tree
FANTASTIC 5 Full Anticoagulation Versus Aspirin
and Ticlopidine study
ISAR 5 Intracoronary Stenting and
Antithrombotic Regimen trial
LV 5 left ventricle or left ventricular
MATTIS 5 Multicenter Aspirin and Ticlopidine
Trial after Intracoronary Stenting
MI 5 myocardial infarction
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ative risks were computed for significant correlates; for
continuous variables, these were calculated for the first
versus the third quartile. For interventions in more than one
lesion, angiographic variables of one randomly assigned
lesion were entered into the analysis. Detailed subgroup
analysis and stratification in different risk subsets were made
using the classification and regression tree (CART) (19),
which was based only on independent factors by logistic
regression analysis to reduce the possibility of an interplay of
the risk factors.
RESULTS
During the follow-up of 30 days, 142 events of stent failure
were observed (2.5%): 112 during the first two weeks (early
events; 2.0%) and 30 in the second half (days 15 to 30; late
events; 0.5%). The cumulative event rates of death, nonfatal
MI and angiographically documented stent occlusion are
differentiated in Figure 1. The rate for stent failure calcu-
lated per calendar year was very stable during the study
period from 1994 to 1999: 2.2% in the first year and 2.6%
in the last year (range, 2.2% to 2.9%). The relative number
of late events (overall, 21% of all events) was also stable: 18%
in the first year and 25% in the last year (range 17% to 26%).
The temporal distribution of all events during the 30-day
observation period is shown in Figure 2. This illustrates that
the majority of events occurred on the day of the procedure
(n 5 38) and the second day (n 5 23); together, 43% of all
events. Beyond this accumulation, events of stent failure
were noted on almost every day during the 30-day follow-
up. All deaths during the observation period were of cardiac
or procedure-related origin. All included events of MI were
related to the treated vessel; in nine patients they were due
to side-branch occlusion with a patent stent.
Baseline characteristics of patients without events, with
early events or with late events are listed separately for these
three groups in Table 1. For most of these baseline
characteristics, there were significant differences by univar-
iate analysis among the three groups. Likewise, Table 2 lists
the procedural data for the three groups, revealing several
significant differences. Therefore, we analyzed all factors
with p , 0.10 (by univariate analysis) in a logistic regression
model for stent failure during the first 30 days. This analysis
identified ten clinical, angiographic and procedural factors
as independent risk factors, which are illustrated in Figure 3,
by their relative risk. To differentiate the risk for early and
for late events, all factors were entered into two respective,
separate multivariate analyses. Their results are illustrated in
Figure 4. There is a striking difference between the two
analyses: while angiographic factors of stenosis severity
before the procedure and qualitative and quantitative factors
Figure 1. Cumulative event rates during the first 30 days after the
procedure. Hatched box 5 early events (days 1 to 14); black box 5 late
events (days 15 to 30). MI 5 myocardial infarction.
Figure 2. Temporal distribution of all events. There were 112 events (2.0%) that occurred during the first 14 days and 30 events during days 15 to 30 (0.5%).
Events per day are illustrated in a hierarchial order: hatched box 5 death; white box 5 nonfatal myocardial infarction; black box 5 occlusion.
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of the obtained final result are independent risk factors for
early events, only general clinical (age, hypertension) or
angiographic (LV function) variables are risk factors for late
events.
These independent risk factors for late events were used
to identify groups of patients having specific high or low
risks. The respective results from a CART analysis of these
factors are illustrated in Figure 5. Starting from a rate of
0.5% for stent failure in the total population (circle on top in
Fig. 5), the event rate rises to 0.9% if the patient is .65
years old (49.9% of study population). If these older patients
do not have arterial hypertension (11.6% of the total study
population), the rate increases to 1.6% and peaks at 2.5% for
patients who, in addition, have a reduced LV function (5.0%
of study population). On the other extreme, patients ,65
years old and without reduced LV function (33.3% of study
population) have an event rate of 0.1%.
DISCUSSION
Major findings. This study analyzes the risk of stent failure
(defined as death, MI or angiographically documented stent
occlusion) in an unselected study population with a contem-
porary four-week antithrombotic regimen after coronary
stent placement (aspirin and thienopyridines). Focussing on
the incidence of late events, that is, those occurring during
the second two weeks after the procedure, the study revealed
three major findings: 1) the risk of stent failure decreases
rapidly during the first few days and is very rare in the third
and fourth weeks, with a cumulative rate of 0.5%. 2) The
Table 1. Baseline Clinical and Angiographic Characteristics
No Event
Stent Failure
p ValueEarly Late
Number of procedures 5,536 112 30 —
Women (%) 23.2 29.5 36.7 0.067
Age (yr) 64.2 6 11.1 66.6 6 11.6 70.4 6 11.3 , 0.001
Cardiovascular risk factors (%)
Arterial hypertension 71.4 65.2 53.3 0.034
Hypercholesterolemia 54.4 53.6 40.0 0.29
Diabetes mellitus 20.7 29.5 30.0 0.035
Smoker 42.7 33.0 33.3 0.075
Acute MI (%) 18.8 33.9 20.0 , 0.001
Multivessel disease (%) 72.5 81.3 83.3 0.051
Reduced LV function (%) 35.4 54.5 60.0 , 0.001
Restenotic lesion (%) 16.8 7.1 10.0 0.015
p values as calculated by univariate analysis.
LV 5 left ventricular; MI 5 myocardial infarction.
Table 2. Procedural Data
No Event
Stent Failure
p ValueEarly Late
ACC/AHA type B2/C (%) 75.6 89.3 93.3 , 0.001
Target lesion (%) 0.42
LAD 41.5 43.8 43.4
CX 19.8 15.2 20.0
Left main 1.8 2.7 3.3
RCA 31.0 27.7 23.3
Venous bypass graft 5.9 10.7 10.0
Vessel size (mm) 3.02 6 0.53 3.02 6 0.58 3.00 6 0.47 0.97
% stenosis before PTCA 77.6 6 16.5 84.4 6 15.4 75.2 6 19.9 , 0.001
Lesion length (mm) 12.6 6 7.3 13.9 6 7.6 13.3 6 9.0 0.23
Number of stents placed 1.7 6 1.2 2.1 6 1.3 1.8 6 0.84 , 0.001
Length of stented segment (mm) 20.9 6 13.2 27.6 6 17.1 25.3 6 15.6 , 0.001
Premounted stents used (%) 28.1 31.3 33.3 0.62
Max balloon pressure (atm) 13.7 6 3.0 13.1 6 3.2 13.1 6 4.6 0.053
Balloon/vessel ratio 1.09 6 0.12 1.08 6 0.10 1.09 6 0.11 0.50
% stenosis after stenting 5.2 6 9.1 9.7 6 20.0 4.0 6 8.9 , 0.001
Residual dissection (%) 1.1 10.7 3.3 ,0.001
Final flow grade TIMI 2 (%) 1.4 7.1 6.7 , 0.001
Abciximab therapy (%) 33.8 54.5 43.3 , 0.001
p values as calculated by univariate analysis.
ACC 5 American College of Cardiology; AHA 5 American Heart Association; CX 5 circumflex artery; LAD 5 left anterior descending coronary artery; PTCA 5
percutaneous transluminal coronary angioplasty; RCA 5 right coronary artery; TIMI 5 Thrombolysis In Myocardial Infarction.
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risk of late events is determined by procedure- and operator-
independent clinical factors (age, LV function, arterial
hypertension). This is in contradistinction to the risk of
early events which is predominantly determined by angio-
graphic and procedural factors. These, at least partially,
reflect the success of the procedure and, therefore, can be
influenced by the operator and his/her experience. 3) The
identification of risk factors for late events makes it possible
to define subgroups of patients having specific high or low
risks; in the presence of all risk factors the late event rate is
as high as 2.5%.
Incidence of late events in previous studies with ticlopi-
dine. The necessary length of a post-procedural thienopy-
ridine therapy has not been thoroughly established. The
four pivotal randomized trials proving the efficacy of a
combined antiplatelet regimen with aspirin and ticlopidine
after coronary stent placement had utilized ticlopidine
regimens of at least four weeks (1–4). Late events, that is,
those occurring in the second two weeks were very rare; in
the Intracoronary Stenting and Antithrombotic Regimen
(ISAR) (1), Stent Anticoagulation Restenosis Study
(STARS) (4) and Full ANTicoagulation versus ASpirin and
TIClopidine (FANTASTIC) trials (2), no adverse cardiac
event was observed in the ticlopidine group during the third
and fourth weeks. In the Multicenter Aspirin and Ticlopi-
dine Trial after Intracoronary Stenting (MATTIS) (3), a
study with a specifically high-risk population, one of a total
of 10 observed cardiac events occurred after 27 days. In a
previous retrospective analysis in an unselected patient
cohort, the majority of stent failures occurred within the
first four days (5), with a rapid decline afterwards. This early
risk was paralleled by the statistically detectable delayed
onset of action of ticlopidine. In this previous analysis, the
significant protective effect of ticlopidine was relatively low
during the first three days, with a peak at the eighth day; it
is noteworthy that a statistically significant effect could still
be identified for the later period between the eighth and
30th days. In this time period, one third of all events had
occurred (5).
Comparison of clopidogrel and ticlopidine. In general,
clopidogrel is assumed to have a similar cardiac efficacy as
ticlopidine. Both published randomized trials comparing
ticlopidine and clopidogrel report higher cardiac event rates
with clopidogrel that were not statistically significant
(10,14), but, due to their design, neither had the statistical
power to prove an equivalence or a difference in cardiac
Figure 3. Significant and independent factors for stent failure within the
first 30 days, displayed with their relative risk and 95% confidence interval
(for continuous variables these were calculated for the first vs. the third
quartile: age, 57.0 vs. 72.2 years; length of stented segment, 15 vs. 25 mm;
residual stenosis, 5.5 vs. 10.5%). LV 5 left ventricular; TIMI 5 Throm-
bolysis In Myocardial Infarction.
Figure 4. Significant and independent factors for stent failure differenti-
ating the early period (i.e., the first 14 days) (A) from the late period (i.e.,
days 15 to 30) (B). Factors are displayed with their relative risk and 95%
confidence interval (for continuous variables these were calculated for the
first vs. the third quartile) (Fig. 3). LV 5 left ventricular; PTCA 5
percutaneous transluminal coronary angioplasty.
Figure 5. Risk rates for late stent failure and their relation to significant
risk factors (Fig. 4B). The numbers inside circles represent the rate of
stent failure in this subgroup; the area of a circle represents the size of the
subgroup (in relation to the circle on top, which comprises all analyzed
procedures; n 5 5,611). LV 5 left ventricular.
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efficacy. Considering these data together with more favor-
able results from nonrandomized trials (12,13,17,20), only a
modest level of evidence for the cardiac equivalency of
clopidogrel can be assumed (21,22). Published data on the
late events of stent failure with clopidogrel are limited
because most studies report only cumulative 30-day event
rates (10,12–14); Jauhar et al. (20) had observed a 0.8% rate
of late stent occlusion.
Necessary length of thienopyridine therapy. From all
these data, with the use of ticlopidine and clopidogrel, there
is an evident paucity of late stent failure, which challenges
the principle of a four-week regimen of thienopyridines,
especially for ticlopidine. Therefore, regimens shortened to
two weeks were investigated. In a selected patient popula-
tion, Berger et al. (6) found no adverse cardiac event after
the discontinuation of ticlopidine or clopidogrel (17) after
two weeks. Preliminary data from the Antiplatelet Therapy
Versus Antiplatelet Therapy Alone in Patients at Increased
Risk of Stent Thrombosis (ATLAST) trial indicate that, in
this higher-risk study population, the rate of stent throm-
bosis was 0.3% after two weeks (7); overall, approximately
one fourth of all cardiac events observed in this trial
occurred in this late period. However, all these studies with
thienopyridines were not large enough to distinguish an
incidence of late stent thrombosis between 0% and 0.5% or
even 1%.
Therefore, the current report provides, for the first time,
a reliable figure for the rate of late stent failure with
thienopyridine therapy. The documented rate of late stent
failure of 0.5% is too low to justify a four-week thienopy-
ridine regimen in all patients but too high to endorse a
two-week regimen for all. It is, therefore, crucial to stratify
patients, to identify risk factors and to adjust the length of
therapy accordingly. In this study, we performed logistic
regression analysis to identify independent risk factors for
late stent failure. In patients with all three significant risk
factors, the rate of late stent failure was 2.5%. Hence, a
four-week thienopyridine regimen seems advisable for these
high-risk patients. On the other hand, this risk stratification
will also make possible the identification of a much larger
group of patients with a lower risk in whom a two-week
regimen might suffice. Their lower cardiac risk must be
weighted against the increasing risk for noncardiac side
effects. Because this risk is lower with clopidogrel than it is
with ticlopidine, the group of patients optimally stratified to
a two-week clopidogrel regimen is presumably smaller than
it would be if ticlopidine is used. Therefore, these data
refine our knowledge of the feasibility of a two-week
thienopyridine regimen, as suggested by Berger et al. (6,17).
Risk factors for early versus late stent failure. This is the
first study to differentiate risk factors for early versus late
events; previous analyses studied all adverse cardiac events of
the first four weeks together. Because the majority of events
occur during the first few days, these analyses predominantly
reflect the risk for early stent failure. Our analysis of the risk
during all four weeks together (Fig. 3) is in keeping with the
results from these previous analyses (5,23,24). These had
identified the predominant influence of angiographic and
procedural risk factors for early outcome, along with age,
LV function, unstable coronary syndromes and diabetes.
Our data differentiating the risk of early versus late stent
failure (Fig. 4, A and B) illustrate a particular distinction:
early risk is largely dependent on procedural factors that (at
least partially) can be influenced by the operator’s stent
placement technique and skills, but late risk is predomi-
nantly determined by unalterable factors such as age, LV
function and systemic hypertension.
Risk factors for late stent failure. Age and impaired LV
function are known risk factors for adverse outcome after
stent placement (5,23,24), as well as after percutaneous
coronary interventions in general (25). In addition, our
analysis identified the presence or history of arterial hyper-
tension as a protective factor. Previous reports have been
inconsistent on the role of systemic hypertension: although
it has been described as a predictive factor for acute closure
after standard percutaneous transluminal coronary angio-
plasty (26), such a relation was not confirmed in recent
analyses for stent placement (5,23,24). An opposing, that is,
protective, effect of arterial hypertension has been described
for patients with primary angioplasty in acute MI; higher
systolic pressure was associated with a lower incidence of
death and repeat MI during early follow-up (27). Such a
relation might have affected our analysis, considering that
approximately 20% of patients presented with acute MI.
However, these data are qualified by the difficulty in
establishing arterial hypertension as a definite cardiovascular
risk factor in an individual patient presenting with high
systemic pressure at baseline catheterization but no previous
history. Therefore, further studies are needed to sufficiently
describe the role of arterial hypertension for early outcome
after stent placement.
Abciximab use and incidence of stent failure. In our
study, patients with stent failure had received abciximab
significantly more frequently, particularly patients with early
events (54.5% vs. 33.5% in patients without events). These
data have to be interpreted with caution in view of the actual
indication for treatment. Approximately 20% of patients
included in our analysis had presented with acute MI, today
an established indication for glycoprotein IIb/IIIa inhibitors
(28,29). Beyond this indication, abciximab was adminis-
tered in patients with complicated procedures and subopti-
mal angiographic results, reflecting a risk stratification based
on our previous analyses (5,30). Therefore, our data reflect
the selective use of this drug rather than a negative effect of
abciximab administration. Furthermore, we assume that the
administration of glycoprotein IIb/IIIa inhibitors in selected
patients deriving particular benefit from such therapy (29)
somewhat diluted our results and reduced the sensitivity to
detect risk factors, especially for early events.
Study limitations. The available data for this study are not
sufficient to analyze the risk for hematologic side effects of
thienopyridine therapy, because routine blood counts were
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not performed after discharge from the hospital. During the
hospital stay (typically three days), we did not observe any
severe ticlopidine-induced neutropenia or thrombocytope-
nia. However, these limited data do not permit the estab-
lishment of a reliable figure for the rate of severe hemato-
logic complications.
Our definition of stent failure comprised death, MI and
angiographically documented stent vessel occlusion in order
to summarize stent thrombosis together with all clinically
relevant cardiac events. This figure truly reflects the clinical
success of an interventional procedure but is not identical to
the actual incidence of stent thrombosis. For example,
clinically silent occlusions may have been missed because
repeat angiography was not routinely performed after 30
days but, typically, performed for recurrent symptoms sug-
gestive of ischemia. Furthermore, stent vessel occlusion was
not securely established in all cases of death, although all
were of cardiac or procedure-related origin.
There are specific differences in methodology between
our patient cohort and those of previous reports that might
qualify as a direct comparison. We did not use intravascular
ultrasound to confirm the final procedural result. Previous
studies have suggested that intravascular ultrasound guid-
ance may improve the short-term and long-term results
(31,32) and may lower rates of stent thrombosis (33). We
included a small number of patients with final TIMI-2 flow,
but only if there was no visible dissection and the vessel had
been totally occluded before the procedure. This factor was
an independent risk factor for stent failure during the
30-day follow-up. Finally, the study period comprises the
introduction of IIb/IIIa inhibitors. For any comparison, it
should be considered that the overall use of these com-
pounds was relatively low (34.2%). Additional studies are
needed to further clarify these differences and their specific
impact.
This analysis included only patients who had received a
four-week ticlopidine regimen. Therefore, definite conclu-
sions should be limited to such patients and should not be
extrapolated to patients with a two-week regimen or to
patients receiving clopidogrel. Although late events are
presumably more frequent if thienopyridines are discontin-
ued after two weeks, adequately sized randomized trials are
essential to address the necessary length of thienopyridine
therapy. In view of the substantially lower rate of severe
hematologic side effects with clopidogrel, dissimilar conclu-
sions concerning risks and benefits of two-week therapy of
the two drugs are likely. Until such studies have been done,
recommendations for a general reduction of the thienopy-
ridine regimen to two weeks are not advisable.
Conclusions. In this study in a large, unselected popula-
tion of 5,678 patients with a four-week ticlopidine regimen,
late stent failure is a rare event (0.5%). Risk factors for these
rare complications are older age and poor LV function, with
arterial hypertension as a protective factor. In contradistinc-
tion to late events, early events are determined by angio-
graphic factors and procedural success, which are at least
partially operator-dependent.
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